Livestreamed on Wednesday, October 29th – 1:00-1:45 pm Eastern – Biosimilars Webinar Series
Sanya Sukduang, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Anthony C. Tridico Ph.D., Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
With passage of both the America Invents Act and the Biologics Price Competition and Innovation Act, and the impending implementation of the European Unified Patent Court, Reference Product Sponsors need to be prepared for a coordinated, global attack on their patent portfolios protecting their valuable biological assets. Indeed, biosimilar applicants now have the ability to not only potentially remove patent barriers in the U.S. well in advance of submitting their ABLA, by utilizing one of the new Post Grant Challenges, but can also simultaneously attack the European equivalents via EPO Opposition and in the future a central revocation at the Unified Patent Court. These new developments provide biosimilar applicants with options for expedited, and less expensive, proceedings. During this webinar, our panelists will address the recent trends in Post-Grant filings in the life sciences space, how the Unified Patent Court will work, and share their thoughts and insights on how Reference Product Sponsors can better prepare themselves to defend their patent portfolios on a global scale.
Time will be reserved for Q&A at the conclusion of the panel.